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Background: Although guidance on good research practice in health economic modeling is 
widely available, there is still a need for a simpler instructive resource which could guide a 
beginner modeler alongside modeling for the first time.
Aim: To develop a beginner’s guide to be used as a handheld guide contemporaneous to the 
model development process.
Methods: A systematic review of best practice guidelines was used to construct a framework of 
steps undertaken during the model development process. Focused methods review supplemented 
this framework. Consensus was obtained among a group of model developers to review and 
finalize the content of the preliminary beginner’s guide. The final beginner’s guide was used to 
develop cost-effectiveness models.
Results: Thirty-two best practice guidelines were data extracted, synthesized, and critically 
evaluated to identify steps for model development, which formed a framework for the begin-
ner’s guide. Within five phases of model development, eight broad submethods were identified 
and 19 methodological reviews were conducted to develop the content of the draft beginner’s 
guide. Two rounds of consensus agreement were undertaken to reach agreement on the final 
beginner’s guide. To assess fitness for purpose (ease of use and completeness), models were 
developed independently and by the researcher using the beginner’s guide.
Conclusion: A combination of systematic review, methods reviews, consensus agreement, and 
validation was used to construct a step-by-step beginner’s guide for developing decision analytical 
cost-effectiveness models. The final beginner’s guide is a step-by-step resource to accompany the 
model development process from understanding the problem to be modeled, model conceptual-
ization, model implementation, and model checking through to reporting of the model results.
Keywords: step-by-step guide, modeling, cost-effectiveness analysis, decision analysis, eco-
nomic evaluation
Introduction
In countries where health technology assessment mechanisms are well established, 
decision analytical cost-effectiveness models (subsequently referred to as models) 
play a pivotal role in addressing difficult health-care decisions. Developing models 
is a complex process – it requires numerous steps and different skills are required to 
complete each step in a way that adheres to best practice in modeling.
In 2012, the International Society for Pharmacoeconomic and Outcomes Research 
(ISPOR) and the Society for Medical Decision Making published an update of the 
2003 recommendations for best practices in modeling.1–7 These publications set out 
the “gold standard” of modeling practice; however, by their own admission they are 
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“not intended as primers on their subjects”1 and may not be 
well understood by those embarking on modeling for the 
first time.1,8 Few resources are available to accompany the 
process of model development. Chilcott et al suggested that 
“although checklists and good modelling practice have been 
developed, these perhaps indicate a general destination of 
travel without specifying how to get there.”8 This research 
directly addresses this gap by constructing a beginner’s guide 
(BG) to modeling to be used by model developers contem-
poraneous to model building. The objective is to construct 
a resource that is more basic than the ISPOR guidelines to 
improve the ease and accuracy by which a new modeler learns 
to model. For example, let us presume that a new researcher 
embarking on practical modeling for the first time consults 
the ISPOR guidelines and begins conceptualizing the model. 
The details of model conceptualization set out by Roberts et 
al and their supplementary material are very comprehensive 
in their guidance as to what to do and they include how to go 
about doing it.2 However, after conceptualization,2 readers 
are guided according to the type of model they will develop 
(State Transition Modelling,4 Discrete Event Simulation,3 or 
Dynamic Transmission Modeling5) and it is difficult for nov-
ice modelers to fill this gap of selecting an appropriate model 
structure. What would be useful is a resource that bridges this 
gap and potentially guides the modeler through something 
more aligned to the algorithm set out by Barton et al9 or the 
taxonomy of Brennan Chick and Davies.10 Therefore, a valu-
able resource would be one which guides the novice modeler 
through each step in the model development process and is a 
more elementary and supportive resource. What is required is 
a hybrid of best practice recommendations and a primer-style 
instructive text to enable early modelers to quickly achieve 
standards of modeling aspired to by ISPOR.
Aim
The aim of this research is to develop a BG to support model 
developers alongside the development of decision analytical 
cost-effectiveness models.
Methods
Four phases of research were undertaken to develop the BG, 
which are shown in Table 1 and described below.
It was necessary to develop the BG incorporating two 
components: the first, an exhaustive list of steps involved 
in the model development process, and the second, an 
“instructive statement” attached to each step setting out 
any guidance, considerations, or recommendations related 
to carrying out that step. For example, one step could be 
to define the perspective of the model analysis and the 
instructive statement could potentially read something 
like: “consider a payer perspective when [...]” and so on. 
To achieve this level of detail, it was necessary to first do a 
systematic review of guidelines (Phase I) to derive the list 
of all possible steps, and then a methods review (Phase II) 
to develop the instructive component of the BG for all steps, 
as described below.
In Phase I, a systematic review of best practice guidelines 
was performed to identify all steps potentially undertaken 
during model development. Best practice guidelines were 
defined as publications intended for the purpose of improv-
ing the methods and quality of models published by health 
economics experts or organizations, such as ISPOR. Through 
a process of data extraction, deductive reasoning, and guide-
line synthesis, an exhaustive list of steps used in developing a 
model was constructed. Full details of the systematic review 
are provided in the Supplementary materials.
For Phase II, the steps identified in Phase I were grouped 
into submethods and focused literature searches were per-
formed to identify methods literature for each submethod. 
For example, when developing a model, it is necessary to 
identify resources and value those resources. A focused 
review was performed to identify best practice in identifying 
and valuing resources in order to include in the BG “how” 
to go about doing these two steps. Review of methods 
papers informed the “how to” part of the BG. Full details 
of the focused searches are provided in the Supplementary 
materials.
Table 1 Methods used to develop the beginner’s guide (BG) to decision analytic cost-effectiveness modeling
Research Phase I Phase II Phase III Phase IV
Method Systematic review Submethods review Nominal group technique (consensus 
agreement)
Validation
Objective Review of best practice 
modeling guidelines
Review of submethods literature To reach agreement on the draft BG To test the usability and 
completeness of the BG
Outcome An exhaustive list of steps 
undertaken to develop a 
model
The guidance, recommendation, or 
instructive statement to support 
HDFKVWHSLGHQWLÀHGLQ3KDVH,
$ÀQDOL]HG%* Revised guide to include 
reviewer feedback
Output 
(result)
Framework for developing 
the BG
Draft BG BG ready for testing Tested and improved 
BG
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In Phase III, the preliminary BG was subjected to a con-
sensus approach to evaluate whether it was current (included 
all information aligned with current methodological think-
ing in modeling), complete (covered all relevant aspects of 
model development), and clear (logical and unambiguous). 
A modified nominal group technique consensus method11 
was used combining private (electronic) feedback in round 1 
and interactive (face-to-face) feedback in a structured format 
with a facilitated meeting in round 2.
In round 1 of the consensus phase, the BG was distributed 
electronically via email to participants for familiarization, 
review, and feedback. For each model development step, 
participants were asked whether the step should be included, 
excluded, or reworded. Where ≥75% of respondents sup-
ported inclusion or exclusion of the step, this was considered 
final and not taken forward to the second consensus phase. 
Where no consensus was reached or ≥50% of the experts 
suggested rewording, the issue was instead addressed in 
round 2. In this way, the face-to-face time with experts was 
prioritized toward dealing with issues in which broad con-
sensus did not already exist.
In Phase IV, two independent novice modelers at the 
University of Leeds developed a model using the guide. They 
evaluated the guide with respect to whether they understood 
the steps, found them useful, and performed them at that 
time point during the model-building process. In addition, 
the researcher redeveloped a case study model consisting 
of a five-state Markov model and recorded each step in the 
model-building process to evaluate the completeness of 
the guide.
Results
The BG is designed to be used by a beginner modeler along-
side the model-building process and it is therefore necessary 
to structure the content in alignment with the model develop-
ment process. Current literature divides the modeling process 
into a number of phases. The first phase addresses the ques-
tion of what is to be modeled and looks at understanding the 
real-world decision problem and its context.8,12–14 Models, 
by their nature, simplify a complex system into one that can 
be captured using less complex mathematical methods. The 
second phase requires a model developer to consider how the 
real-life decision problem translates into a model.  During this 
phase, there is a tension between what Sonnenberg describes 
as the “theoretical model,” which represents an understand-
ing of the natural history/biological fact, and the “practical 
model,” which is the “most detailed model which can be 
constructed given the limitations of the available data and 
the need for the model to be understood.”14 A third phase 
involves the actual programming of the model,8,12,14 including 
obtaining the data to be used in the model.15 In the fourth 
phase, the different strategies are evaluated13 by considering 
likely outcomes, validation of these outcomes, and sensitiv-
ity analysis.8,15 The final phase involves engaging with the 
decision-makers8,13 and disseminating the model results along 
with uncertainty of the model. These model phases are itera-
tive, and it is common for developers to go back and forth 
between different phases of model development.8
The phases of model development are summarized in 
Table 2.
Within each model development phase, multiple steps 
are undertaken. The number and order of these steps may 
differ across cases and are influenced by factors, including 
the type of model being developed, modeler’s preference, 
and data available to populate the model (eg, if using 
primary data from a randomized controlled trial, then the 
literature search strategy will differ versus if secondary data 
are being used to populate the model). The BG is structured 
according to the five phases of model development set out 
by Chilcott et al.8
3KDVH,²V\VWHPDWLFUHYLHZ
Thirty-two best practice guidelines were data extracted, 
synthesized, and critically evaluated to identify steps taken 
and submethods used in model development. For a list of 
guidelines, please see Supplementary materials. A total of 
148 steps involved in model development were identified 
and arranged into eight broad submethods, namely, evidence, 
model structure, resource valuation, effectiveness, uncer-
tainty, validity, reporting, and general.
3KDVH,,²PHWKRGRORJLFDOUHYLHZV
Developing a model involves many so-called submethods. For 
example, the steps relating to the evidence used in a model 
may be grouped together in an “evidence” submethod, which 
covers literature searching and review, evidence selection, 
and evidence grading. Similarly, separate submethods can 
be described for aspects, such as measuring and valuing 
health-related quality of life, characterizing uncertainty, and 
testing the validity of models. Nineteen submethod reviews 
were undertaken to identify and review literature relating to 
the eight submethods identified in Phase I. A summary of 
the literature reviewed for each submethod is shown in Table 
3 and described below.
The evidence submethod included the steps involved in 
literature searching and review, literature selection,  evidence 
 
Cl
in
ico
Ec
on
om
ics
 a
nd
 O
ut
co
m
es
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
9.
11
.2
3.
35
 o
n 
16
-D
ec
-2
01
6
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
ClinicoEconomics and Outcomes Research 2016:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
576
Rautenberg et al
grading, and selecting input parameters for a model. Five 
 publications were reviewed to explore search methods and the 
use of evidence in models,16,17 evaluate methods for selecting 
evidence based on quality and other criteria, respectively,18,19 
and discuss methodological challenges when using evidence 
for modeling.20
The model structure submethod was defined as processes 
(eg, algorithms) and methods to select the most appropriate 
model structure. Three papers were reviewed which provide 
a taxonomy of model structures or guidance on choosing 
between them.9,10,21
The resource valuation submethod was defined as the 
methods used for identifying and quantifying relevant 
resources, assigning costs to resources, and the discount-
ing of costs. Eight papers were relevant for the submethod 
dealing with resource valuation, including those dealing 
with  quantifying resources,22 valuing resources,23,24 and 
approaches for discounting.25–29
The effectiveness submethod was defined as having two 
components. The first being capturing the measurement 
of clinical benefits both with respect to efficacy data from 
randomized controlled trials, and effectiveness data from 
other studies, such as observational studies and registries. 
The second component focuses on health-related quality 
of life with emphasis on methods to describe (measure) 
health-related quality of life, such as, disease-specific, 
disease- and symptom-specific, and generic measures (eg, 
Euro-QOL EQ-5D, SF-6D, Health Utilities Index). This 
component also includes methods to value health-related 
quality of life (standard gamble, time trade off, rating 
scales); means of eliciting preferences (patient, medical 
experts, general population); and discounting outcomes. 
Relevant guidelines here include an overview of general 
issues regarding effectiveness,30–32 adverse events,33 qual-
ity of life measurement,34 and methods used to incorporate 
quality of life into models.35
The uncertainty submethod was defined as types of 
uncertainty and methods to characterize uncertainty. A total 
of 12 papers were reviewed for uncertainty, including several 
that contribute to an understanding of  terminology,15,36–40 
Table 2 Consolidated summary of descriptions of the model development process
Briggs 2000 
(alongside RCT)15
Sonnenberg (1994)14 Stahl (2008)13 Sargent 
(2010)12
Chilcott (2010)8 Tappenden 
(2012)66
What will be modeled?
– 1. Biological truth to be 
modeled
2. Describe the system under 
study
3UREOHPHQWLW\ 1. Understanding the decision 
problem
How will it be modeled? (conceptual)
1. Setting a reference 
case of methods
2. Theoretical model 
(represents an 
understanding of the 
biological truth)
3UDFWLFDOPRGHO´PRVW
detailed model which can 
be constructed given the 
limitations of the available 
data and the need for the 
model to be understood” )
1. Describe the development of 
a simulation model
2. Conceptual 
model
2. Conceptual modeling (conceiving 
the model, cognitive processes of 
thinking about the model and the 
potential methods to be used, 
information available, etc). 
´'HÀQLQJWKHERXQGDU\
and depth of a model”8 and 
identifying critical factors for 
inclusion in the model are 
important during this phase.
Building the model
2. Specifying clinical/
demographic patient 
characteristics
4. Implementation model 
(actual model in a software 
package)
– 3. Computerized 
model
3. Implementation of the model 
(the actual programming of the 
model software)
Running the model
3. Applying Bayesian 
methods to 
estimate data and 
distributions for the 
UXQQLQJRI36$
– 3. Evaluate the consequences 
of a given strategy
4. Explore the model
– 4. Model checking phase is 
undertaken to verify that the 
model is working as it should be 
DQG´LQFOXGHVDOODFWLYLWLHVXVHGWR
check the model”8
Disseminating the model results
– – 3UHGLFWRUIRUHFDVWWKH
behavior of the system and 
persuade decision-makers 
through consensus and 
evidence
– 5. Engaging with the decision 
(reporting of the model results 
and answering the original 
decision problem)
Note: The numbering in this table (read vertically within each column) corresponds to the order of the task described by the original (referenced) author.
Abbreviation:5&7UDQGRPL]HGFRQWUROOHGWULDO36$SUREDELOLVWLFVHQVLWLYLW\DQDO\VLV
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methods to address uncertainty in general,41,42 and more 
focused guidelines concentrating on parameter uncer-
tainty43,44 and structural uncertainty.45,46
Ten key publications formed the basis of the review of 
validity, which covered types of validity and validation 
 methods.8,12,47–52 Schlesinger sets out recommended terms 
to describe model credibility,47 while Sargent defines and 
outlines methods of validation and verification.12 Other papers 
included a framework for assessing validity in models48 or 
applied broad issues in validation using specific models.49,50 
In several other papers, validity is considered even though 
the focus of the papers appears to lie elsewhere.8,51,52
Model reporting was def ined as any numeric or 
graphical results of a model, which included incremen-
tal  cost-effectiveness ratio and confidence intervals; 
cost-effectiveness plane; cost-effectiveness acceptability 
curve; cost-effectiveness acceptability frontier; net benefit 
approach; and value of information analysis. For report-
ing of models, in six papers the graphical presentation 
of uncertainty from probabilistic sensitivity analyses is 
considered.15,53–57 Several older papers compare meth-
ods of presenting uncertainty around incremental cost-
effectiveness ratios,36,58–61 with more recent papers instead 
considering the use of the net benefit approach and value 
of information analysis.38,42 Several other papers did not fit 
neatly into the defined submethods and were included in 
a general section which covered topics, such as methods 
to achieve transparency,62 selecting time horizons,63 and 
subgroup analysis.40
As a result of the submethods literature above, each of 
the 148 steps involved in model development were expanded 
upon to take the form of an instructive or directive statement/
step along with explanatory notes, examples, and relevant 
references for each of the steps. This submethod review 
thereby informed the content of the BG, which was subjected 
to consensus agreement.
Table 3 Scope of review of eight submethods to inform the content of the beginner’s guide
Scope of submethod review Literature reviewed
1. Evidence
Literature search retrieval and selection, selecting evidence for input 
parameters, evidence grading if relevant
Booth (2010)163DLVOH\17; Braithwaite et al (2007)18; Nuijten (1998)19; 
Cooper (2007)20
2. Model structure
General methods for selecting model structure Barton et al (2004)9; Cooper et al (2007)21; Brennan et al (2006)10
3. Resource valuation
Identifying and valuing resources, discounting Miners (2008)22, Hay et al (2010)23; Shi et al (2010)24; Brouwer et al (2005)25; 
Claxton et al (2006)26; Claxton et al (2011)27; Gravelle et al (2007)28; 
Nord (2011)29
4. Effectiveness (health outcomes)
&OLQLFDOKHDOWKHIÀFDF\HIIHFWLYHQHVVPHWKRGVWRGHVFULEH
KHDOWKUHODWHGTXDOLW\RIOLIHGLVHDVHVSHFLÀFGLVHDVHDQG
V\PSWRPVSHFLÀFJHQHULFPHDVXUHV(XUR42/(4'6)'
Health Utilities Index). Methods to value health-related quality of life 
(standard gamble; time trade off; rating scales), eliciting preferences 
(patient; medical experts; general population), discounting outcomes
Gray et al (2010)30; Craig et al (2009)33; Brazier (2008)31; Neumann et al 
(2000)32; Gold et al (2002)35; McDonough and Tosteson (2007)34
5. Uncertainty
Types of uncertainty (parameter; methodological, model). 
Methods to characterize uncertainty: deterministic (univariate 
and multivariate), probabilistic; model averaging; model selection; 
parameterizing subfunctions
Briggs (2000)15; Briggs and Gray (1999)36; Briggs and Gray (1999)37; 
Claxton (2008)38; Groot Koerkamp et al (2007)57; Sculpher (2008)40; Andronis 
et al (2009)43; Limwattananon (2008)44; Bojke et al (2006)45; Strong (2012)67; 
Brisson and Edmunds (2006)41; Groot Koerkamp et al (2010)42 
6. Validity
Types of validity (face; internal; external; convergent; predictive) and 
validation methods 
Schlesinger (1979)47; Sargent (2010)12; McCabe and Dixon (2000)48; 
Kim and Thompson (2010)49; Sendi et al (1999)50; Halpern et al (1998)51; 
Weinstein (2001)68; Weinstein et al (2003)52; Chilcot et al (2010)8; Stahl (2008)13
7. Reporting
,QFUHPHQWDOFRVWHIIHFWLYHQHVVUDWLRDQGFRQÀGHQFHLQWHUYDOVFRVW
effectiveness plane; cost-effectiveness acceptability curve; cost-
HIIHFWLYHQHVVDFFHSWDELOLW\IURQWLHUQHWEHQHÀWDSSURDFKYDOXHRI
information analysis
Black (1990)69; Briggs and Gray (1999)36; Briggs et al (1997)58; 
Fan and Zhou (2007)59; Dinh and Zhou (2006)603ROVN\HWDO61; 
Barton et al (2008)53; Briggs (2000)15; Fenwick and Briggs (2007)54;  
Fenwick et al (2001)55; Fenwick et al (2004)56; Groot Koerkamp et al (2007)57; 
Claxton (2008)38; Groot Koerkamp et al (2010)42 
8. General
Methods to achieve transparency, selecting time horizons, subgroup 
analysis
Sculpher (2008)40; Eddy (2006)62; Cooper (2007)20
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3KDVH,,,²FRQVHQVXVDJUHHPHQW
For the consensus agreement phase, purposive sampling was 
used to identify experts from across the UK. A total of 22 
experts were originally contacted, of whom 18 responded. 
Of these, six experts contributed in round 1 (with the others 
either not replying at all or not replying in time to allow their 
responses to be incorporated) and 12 contributed in round 2. 
A total of six experts participated in both rounds.
For each of the 148 model development steps, participants 
were asked whether the step should be included, excluded, or 
reworded. Included as such were 133 steps (90%) following 
round 1 and four steps (3%) were excluded at round 1. This 
left ten steps, which were discussed at round 2, in addition 
to four new steps proposed for discussion after feedback in 
round 1.
The final panel invited for round 2 comprised nine 
academics, one industry participant, and two from contract 
research organizations. Five were experts in health economic 
modeling, two in guideline development, and one each in 
health technology assessment, literature searching, utilities, 
uncertainty, and statistics, respectively.
A total of ten experts attended round 2, with their 
responses digitally recorded and transcribed with the attend-
ees’ permission. The number of steps increased from 148 to 
156 after the consensus phase. Please see Supplementary 
materials for the final list of 156 steps.
3KDVH,9²YDOLGDWLRQ
Two researchers provided feedback on three main aspects of 
the guide: whether they understood each of the 156 steps, 
the usefulness of the steps (1= not useful; 2= useful; 3= very 
useful), and whether they undertook the steps during that 
particular phase of model development. The results are sum-
marized in Table 4.
In summary, there seemed to be a good understanding of 
the content of the BG; it was useful for the model develop-
ment process and most of the tasks were timed to coincide 
with the flow of the guide. In response to the feedback 
from Phase IV, a more detailed set of user instructions was 
compiled and links to the relevant literature resources were 
included in the BG.
In a second validation step, one of the authors (TR) 
redeveloped a model developed at the Centre for Health 
Economics, Technology Assessment Group at the University 
of York.64 Independent of the BG, each step of the model was 
undertaken and recorded to complete the development of 
the model according to the finished product. This recorded 
list was then cross-checked with the BG to determine 
whether this step was included in the BG and where it was 
not included, to explain why. The original and redeveloped 
model was a decision tree in Microsoft Excel (Microsoft 
Corporation, Redmond, WA, USA), which evaluated respond-
ers and nonresponders over lifetime duration, and included 
mortality. The model adopted the perspective of the National 
Health Service and Personal Social Services and the model 
output was cost per quality adjusted life year. Health effects 
were measured as quality adjusted life years and both costs 
and outcomes were discounted at 3.5%. Probabilistic and 
deterministic analyses were undertaken.
Limitations
The BG needs to be evaluated with respect to the limita-
tions of the research. Firstly, the foundation for the BG is 
two literature reviews, one focusing on guidelines and one 
on submethods. The guideline review informed the draft 
of the BG consisting of the steps undertaken during model 
 development and was updated in 2011. The steps were 
agreed during consensus development and verified during 
Phase VI. On this basis, an updated review of guidelines is 
not  anticipated to change the steps in the BG substantially. 
Table 4 Validators’ feedback on understanding, usefulness, and 
timing of the steps in the beginner’s guide
Question V1 V2
n (%) n (%)
Total steps 156 100 156 100
Did you understand this step?
Yes 125 80 105 67
No 9 6 1 1
Missing 22 14 50 32
Missing values – input mean 
values for repeated steps*
10 6 38 24
Rate the usefulness of this step on a scale of 1 to 3 (1= not useful; 
2= useful; 3= very useful)
3= very useful 92 59 102 65
2= useful 19 12 3 2
1= not useful 4 3 0 0
Missing values treated as missing 41 26 51 33
Missing values – input mean 
values for repeated steps*
29 19 39 25
Did you perform the step here (or at another stage in the modeling 
process)?
Yes 103 66 91 58
No 27 17 17 11
Missing values treated as missing 26 17 48 31
Missing values – input mean 
values for repeated steps*
14 9 30 19
Note: *Mean entries have been inserted for literature search, source, selection, 
and evidence grading steps, which were rated as done at that time point by both 
validators and useful by V1 and very useful by V2.
Abbreviations: V1, validator 1; V2, validator 2.
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However, the submethod reviews which informed the 
instructive component of each step will need to be updated 
annually as the empirical modeling methods are evolv-
ing in the discipline of health economics. The number of 
experts included in the consensus phase was constrained 
by geographical limitations and research funding; however, 
all experts participated voluntarily and none had any other 
participation in the research. There is a potential to evaluate 
the BG in a wider audience and for a range of model types. 
Moving forward, it would be valuable for more experienced 
modelers to also provide feedback on the BG. As the paper-
based version of the BG was developed, it has evolved into 
an interactive web tool, which may be used to collect user 
feedback. Areas of paucity in the BG reflect the variation 
in the current literature, for example, limited guidance on 
the selection of clinical efficacy and effectiveness data as 
model inputs.20,33,65
No BG of the type reported here can stipulate the “cor-
rect” methods to be used, as this is likely to differ over time 
(with methodological and computational advances) and 
because the choice of appropriate methods is affected by 
the context of the decision to be made. However, in using 
the BG model developers should be confident that they have 
satisfactorily considered, suitably chosen, and can justify 
the submethods used for model development. Chilcott et 
al recognized a need for an aid to achieve best practice and 
considered this “a priority for future development.”8 The 
BG is a sound resource to fill that gap. Irrespective of these 
limitations, the current format of the BG will be of value to 
beginner modelers.
Discussion
The BG is intended to bridge the gap between theory and 
practical model development. The BG is intended as a 
complement to, rather than a replacement of, the ISPOR 
guidelines and this topic is the subject of another paper. In 
summary, there are three main distinguishing features of the 
BG. Firstly, the ISPOR guidelines set out a set of recommen-
dations while the BG sets out a comprehensive list of steps to 
be considered and, if applicable, undertaken contemporane-
ous to model development. Secondly, the ISPOR guidelines 
are arranged according to model conceptualization, three 
specific modeling techniques, uncertainty, and validation, 
whereas the BG is arranged according to the five phases of 
model development. Thirdly, the BG takes a novel approach 
to integrating the concepts of uncertainty and validation 
into each step of model development rather than discrete 
concepts to be addressed separate to, or upon completion of, 
model development. Arguably, if model developers are made 
aware that a certain step in the model-building process may 
contribute to greater or lesser uncertainty in the model struc-
ture/results, then they are better informed to make adequate 
judgments as to how to minimize the uncertainty introduced 
during this step and also to consider the impact of potential 
uncertainty within and around the model results. Similarly 
when using the BG, a modeler is made aware of the impact 
of each step on model validity and is therefore better able 
to maximize the validity of the model. For example, during 
model conceptualization the modeler is made aware of the 
importance of consulting clinical experts to verify the face 
validity of the model – in this way, the modeler is aware of 
how this step potentially influences the face validity of the 
model. Each step is also, where relevant, linked to bias and 
heterogeneity throughout. For example, when selecting the 
comparator, selecting the relevant comparator influences 
the face validity of the model and if incorrectly chosen may 
introduce bias into the model (eg, if a costly comparator 
is selected). The BG condenses relevant aspects of model 
development into a single, accessible resource to inform 
modelers about the methodology of model development 
while they are going about developing a model. Where it is 
able to, it provides direct guidance; otherwise, it lists relevant 
references which describe and discuss potential methods. 
It also includes ancillary resources, for example, a quick 
reference section to evidence selection, detailed information 
on types of uncertainty and validity, and the methods used 
to address both.
The BG is potentially valuable for users of models, both 
by increasing the quality of what it produced and highlight-
ing any deficits in documentation. In this way, it increases 
the transparency of the model development process and 
alerts users to potential sources of bias. Disaggregating the 
process into its smallest steps makes the process explicit 
and clear and the weaknesses of the process can be better 
perceived.
Conclusion
A BG has been developed based on four research methods. It 
has demonstrated usability in the model development process. 
Research is ongoing; however, the BG has the potential to be 
used in the operationalization of best practice recommenda-
tions in modeling.
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